Clinical trial activity remains strong in the area of new vaccine development, as COVID-19 continues to impart tremendous health and societal impact on our world.
What we know as work has experienced a major transformation. This shift and the changes it precipitated have affected how we now conduct and perform monitoring of clinical trials.
Team Veristat Participate in Cycle for Survival 2021 - Virtually
For the past seven years, Veristat has participated in Memorial Sloan Kettering's Cycle for Survival, the movement to beat rare cancers. Founded in partnership with Equinox fitness club back in 2006, this ground-breaking research fundraiser celebrated its 15th anniversary in 2021 and has raised nearly three hundred million dollars for rare cancer research to date.
How We Planned an International Meeting in a Pandemic
Looking back, 2020 has taught us all a few lessons we were not expecting to learn.
An Interview with Kevin Hennegan, Senior Regulatory Strategist, Veristat
An Interview with Dunya Botetzayas, RN, Senior Director of Clinical Monitoring at Veristat
At Veristat our need to manage and work in virtual environments continues to increase. With six offices globally and nearly 300 employees, we are building teams with members spread out in different physical locations. Our geographically dispersed teams continue to grow with our increasing remote employee population; In fact remote workers are our largest growing population with nearly 30 % of our employees working from their home offices.
Our Challenge: Join the Battle to Beat Rare Cancers
Our Impact: $150K Raised to Support Rare Cancer Research
For a fifth consecutive year, Team Veristat accepted this challenge in the 2019 Boston #cycleforsurvival event! We exceeded our goal of raising $50,000 to support rare cancer research.
As a Talent Acquisition Consultant for Veristat, I receive many cover letters and resumes from candidates each day. I am often blown away by the experience, knowledge, and expertise of these individuals and always hope to match their skill sets to one of our current openings.